Treatment of tuberous sclerosis facial angiofibromas with erbium-yttrium aluminium garnet laser and topical sirolimus 0.25% Tüberoskleroz yüz anjiyofibromlarının erbium-itriyum alüminyum garnet lazer ve topikal sirolimus %0,25 ile tedavisi
Turkderm Turkish Archives of Dermatology and Venereology, cilt.54, sa.1, ss.19-21, 2020 (ESCI, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 54 Sayı: 1
- Basım Tarihi: 2020
- Doi Numarası: 10.4274/turkderm.galenos.2019.13845
- Dergi Adı: Turkderm Turkish Archives of Dermatology and Venereology
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.19-21
- Anahtar Kelimeler: Erbium-YAG laser, sirolimus, mTOR inhibitor, angiofibroma
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Although the efficacy of topical sirolimus for facial angiofibromas of tuberosclerosis is now appreciated, drug-induced irrritation complicates the use of the concentration recommended in the literature as 1%. Adjuvant vascular or ablative laser applications may be preferred in adult patients for a variety of purposes, such as treatment of large lesions that tend to be resistant to topical treatment, reduction of topical product concentration and rapid response generation. Herein, we aimed to share the 2-year follow up result of a tuberoussclerosis case where angiofibromas were observed on the chin, malar regions and nose. We combined the full-field erbium-yttrium aluminium garnet laser application with topical sirolimus 0.25% cream on the second month of treatment.